QURE
uniQure N.V.
NASDAQ · NLHealthcareBiotechnology
$39.70-1.37%
Price as of Jul 20, 2026
QURE growth
uniQure N.V. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -10.4%
- EBITDA
- +6.4%
- EBIT
- -12.9%
- EPS
- +20.0%
- Free cash flow
- +2.1%
- Operating cash flow
- -3.5%
Forward estimates
- Revenue
- +179.5%
- EBITDA
- +73.4%
- EPS
- -96.4%
Three-year CAGR
- Revenue
- -46.7%
- EBITDA
- +27.5%
- EBIT
- -1.9%
- Net income
- +16.9%
- EPS
- +29.7%
- Free cash flow
- +4.4%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.